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cessfully developing condition-speciﬁc formularies. Annually an
estimated $456.00 and $1813.00 drug cost savings could be
achieved by the hospice as a result of implementing depression
and CHF formularies.
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DIAGNOSTIC AND SURGICAL CARDIOLOGY UNIT
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OBJECTIVES: Growing interest in the use of Drug Eluting Stents
(DES) in coronary angioplasty has prompted the Health Care
Agency of the Emilia Romagna Region to draw up recommen-
dations for their appropriate clinical use. Since the adoption of
any new technology necessitates economic appraisal, we have
analyzed the resource consumption by type of angioplasty pro-
cedure as well as the impact on the budget of a cardiology
department. METHODS: A retrospective economic evaluation
has been carried out on the angioplasty procedures performed in
2004 in the Cardiology Department of Reggio Emilia hospital.
Using the Activity Based Costing method, detailed hospital costs
have been estimated for each procedure and compared with the
pertinent Italian DRG fees. RESULTS: In 2004, the Interven-
tional Cardiology Department of Santa Maria Nuova Hospital
in Reggio Emilia performed 806 angioplasty procedures for a
total expenditure of €5,176,268. These were: 93 Plain Old
Balloon Angioplasties (POBA) (€487,329), 401 procedures using
Bare Metal Stents (BMS) (€2,380,071), 249 procedures using
Drug Eluting Stents (DES) (€1,827,386) and 63 MIXED proce-
dures (€481,480). Reimbursement via DRG funding amounted
for €5,816,748 (11% for POBA, 50% for BMS, 31% for DES
and 8% for MIXED procedures). The overall case-mix of the
performed angioplasty procedures generated a positive margin
of about €680,480 between the costs incurred and the reim-
bursement obtained. CONCLUSIONS: Analysis of the case-mix
of procedures revealed that, although the adoption of innovative
technologies increases costs, an overall positive margin between
costs and DRG reimbursements can be achieved. It therefore
emerges that, adherence in clinical practice to the guidelines
designed by the Health Care Agency of the Emilia Romagna
Region is economically sustainable from the point of view of the
hospital-enterprise.
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NATIONAL INSTITUTE FOR HEALTH AND CLINICAL
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OBJECTIVES: To review reported economic evaluations of
myocardial perfusion scintigraphy (MPS) for patients with sus-
pected coronary artery disease (CAD); to synthesise and com-
municate two reviews undertaken to support an appraisal of
MPS in this technology by the UK National Institute for Health
and Clinical Excellence (NICE). METHODS: Conduct a sys-
tematic review to identify published studies reporting economic
evaluations comparing diagnostic strategies with and without
MPS in patients with chest pain and/or abnormal resting ECG.
Studies published between 1984 and 2002 were included,
together with two model-based evaluations submitted to NICE
in 2003. Results were summarised by source of data, strategy
comparison and type of patient. Quality of reported studies and
methodological issues were assessed. RESULTS: Twenty-four
studies were identiﬁed: 12 ‘primary’ studies based on analyses of
prospective or retrospective data and 12 studies based on deci-
sion-analytic modelling. Twenty studies were based in the US and
4 in the UK, one of which used data from a range of European
countries. Many studies reported that MPS was a cost-effective
alternative to Exercise ECG (ExECG) prior to coronary angiog-
raphy (CA) in patients at intermediate/high risk of CAD. Evi-
dence for the cost-effectiveness of adding MPS after ExECG (in
patient’s positive on ExECG) was less conclusive. Compared
with MPS, direct CA was generally not cost-effective in patients
at intermediate risk, but cost-saving for patients at high risk.
Studies were of variable quality; for example primary studies
based on short term outcomes, and failure to present incremen-
tal comparisons. The use of CA as a gold standard for functional
imaging tests which provide additional information to the degree
of vessel stenosis may be problematic. CONCLUSION: There 
is evidence for the cost-effectiveness of MPS in patients at 
intermediate risk of CAD. It would be valuable to conﬁrm this
with longer term prospective studies and improved economic
modelling.
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OBJECTIVES: To estimate the drug acquisition cost savings for
third payer payers (TPPs) with the availability of generic sim-
vastatin in the United States. METHODS: A deterministic study
ascertained the potential cost savings for TPPs in the year fol-
lowing generic simvastatin availability. The study focused on
patients requiring cholesterol reduction (>30% LDL-C reduc-
tion). Annual national statin prescription sales (November
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2004–October 2005) were obtained, and a dose interchange
table identifying the statin switches providing an LDL-C lower-
ing effect within 10% of the entry drug was developed. The study
assumed all patients requiring a higher level of LDL reduction
would switch from other equivalent statin doses to simvastatin
20 mg daily. Two different assumptions with four cost scenarios
for future generic simvastatin prices were tested: 20% rebate for
branded statins, a 50% discount rate, and $5 generic and $15
brand co-payments (assumption 1) and 20% rebate for branded
statins, a 60% discount rate, and $10 generic and $30 brand co-
payments (assumption 2). RESULTS: With the baseline assump-
tions in the study, total costs to TPPs for branded statins were
$5.57B (assumption 1) and $4.62B (assumption 2). Switching
patients to generic simvastatin lowered total costs to $4.54B and
$3.25B, respectively, providing potential costs savings for TPPs
of $1.03B to $1.37B. One-way sensitivity analyses varying the
purchasing discount rate for generic simvastatin from 40%–75%
in assumption 1, found the range of cost savings to be $0.06B–
$3.46B; varying the discount rate from 50%–75% in 
assumption 2 found a range of cost savings of $0.4B–$2.83B.
CONCLUSION: The switch to generic simvastatin 20 mg for
patients requiring cholesterol reduction yielded potential annual
cost savings for TPPs over one year. Other long-term studies
focusing on the economic impacts on TPPs are encouraged to
evaluate potential cost savings following the availability of other
generic statin drugs.
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OBJECTIVES: Recently published data have increased interest
in high clopidogrel loading doses (>300 mg) in acute coronary
syndrome (ACS) patients undergoing percutaneous coronary
intervention (PCI). The purpose of this study was to examine
clopidogrel patterns of use in the hospital setting in ACS/PCI
patients residing in Europe. METHODS: This was a retrospec-
tive study using the IMS Health Acute Cardiovascular Analyzer.
This is a physician-reported registry in Germany, France, Italy,
Spain, and the UK. Data collection timeframe was January–
November 2005. The standard dose clopidogrel group was
deﬁned as <300 mg. Demographic and health characteristics
were compiled for the entire cohort and by country. RESULTS:
Over 400 cardiologists reported data on 4393 ACS patients who
received clopidogrel and underwent PCI. Patient count by
country was: Germany-1117, France-1048, Italy-598, Spain-
993, UK-637. Mean age was 63 + 12.2 (SD) years; 71% were
male. Common comorbidities and risk factors were: hyperten-
sion 66%, dyslipidemia 63%, diabetes 31%, prior myocardial
infarction (MI) 13%. Medications prior to admission were:
clopidogrel 17%, statins 26%, aspirin 27%. The index diagno-
sis was: ST-elevation MI 45%, non ST-elevation MI 29% and
unstable angina 26%. Timing of clopidogrel administration in
relation to PCI was: 23.9% pre-PCI (of which, 2% were >12
hours pre-PCI), 10.9% at PCI and 53.4% after PCI. Loading
dose ranged from 75–900 mg. Dosage <300 mg by country was:
Germany 80%, France 85%, Italy 91%, Spain 95%, UK 81%.
Approximately 96% of patients were discharged on clopidogrel
and the most common planned duration was 6–12 months
(56.6%) followed by >12 months (13.6%). CONCLUSIONS:
These recent data indicate many patients did not receive clopi-
dogrel prior to PCI and higher loading doses (>300 mg) were
uncommon. The vast majority of patients received clopidogrel
upon discharge with planned duration of therapy of 6–12
months. These data may be useful benchmarks for later com-
parison to treatment guidelines.
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OBJECTIVES: To compare claims data on bleeding complica-
tions in ACS patients treated with clopidogrel vs. aspirin/heparin
undergoing catheterization prior to coronary artery bypass graft-
ing (CABG). METHODS: Patients >18 years of age with an ACS
diagnosis between 2000 and 2004 were identiﬁed using ICD-9
codes. Treatment patterns and outcomes were compared across
two cohorts: patients on clopidogrel +/− aspirin, heparin, or
IIbIIIa antagonists, and those on aspirin or heparin only. Claims
for CABG and catheterization prior to CABG were evaluated.
Among CABG patients who received clopidogrel, distribution of
days clopidogrel was discontinued pre-surgery was examined.
Claims related to bleeding complications among patients with
catheterization prior to CABG were evaluated using logistic
regression controlling for age, race, time to CABG, IIbIIIa 
exposure, and hospital size. RESULTS: We identiﬁed 25,289
clopidogrel patients and 21,688 aspirin/heparin patients. The
clopidogrel cohort was signiﬁcantly younger (65.6 versus 69.7,
p < 0.0001) with a higher proportion of male patients (62.8%
versus 54.7%, p < 0.0001). A total of 2535 clopidogrel patients
(10%) and 4358 aspirin/heparin patients (20.1%)underwent
CABG; of those, 1633 clopidogrel (64.4%) and 2053 aspirin/
heparin (47.1%) patients underwent catheterization prior to
surgery during the index admission. Among these clopidogrel
patients, 1791 (70.6%) discontinued clopidogrel prior to CABG;
a majority discontinued either the day of (41%) or the day before
(20.5%) surgery. Among patients undergoing catheterization
prior to CABG, claims related to bleeding complications were
signiﬁcantly more likely in the clopidogrel cohort compared to
the aspirin/heparin cohort after adjusting for covariates (OR
1.84, 95%CI 1.08–3.13). CONCLUSION: A majority of ACS
patients treated with clopidogrel and undergoing catheterization
and CABG discontinue clopidogrel closer to CABG than the rec-
ommended ﬁve days pre-surgery (US Package Insert). Addition-
ally, such patients may be at higher risk for bleeding than patients
treated with aspirin/heparin only.
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OBJECTIVES: Atrial ﬁbrillation (AF) is the most common heart
arrhythmia affecting more than 6% of elderly people. The
annual risk of stroke in patients with AF not taking Vitamin-K
antagonists (VKAs) is 3–5%. Anticoagulation with a prothrom-
bin time (INR) of 2–3 has demonstrated effective primary pro-
phylaxis. This multi-centre observational study was conducted
to gain knowledge of the current treatment patterns of AF in
Germany, their clinical results and related resource utilization.
